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Abstract
We present the results of a comparative gene expression analysis of 15 metastases (10 regressing
and 5 progressing) obtained from 2 melanoma patients with mixed response following different
forms of immunotherapy. Whole genome transcriptional analysis clearly indicate that regression
of melanoma metastases is due to an acute immune rejection mediated by the upregulation of
genes involved in antigen presentation and interferon mediated response (STAT-1/IRF-1) in all
the regressing metastases from both patients. In contrast, progressing metastases showed low
transcription levels of genes involved in these pathways. Histological analysis showed T cells and
HLA-DR positive infiltrating cells in the regressing but not in the progressing metastases.
Quantitative expression analysis of HLA-A, B and C genes on microdisected tumoral regions
indicate higher HLA expression in regressing than in progressing metastases. The molecular
signature obtained in melanoma rejection appeared to be similar to that observed in other forms of
immune-mediated tissue-specific rejection such as allograft, pathogen clearance, graft versus host
or autoimmune disease, supporting the immunological constant of rejection. We favor the idea that
the major factor determining the success or failure of immunotherapy is the nature of HLA Class I
alterations in tumor cells and not the type of immunotherapy used. If the molecular alteration is
reversible by the immunotherapy, the HLA expression will be upregulated and the lesion will be
recognized and rejected. In contrast, if the defect is structural the MHC Class I expression will
remain unchanged and the lesion will progress.
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Different protocols of melanoma immunotherapy have been used during the last decade,
including interferon alpha 2b, interleukin 2 and 12 or more specific ones, such as autologous
vaccination with naked peptides, dendritic cells, or plasmid DNA, or adoptive transfer of
tumor-specific cytotoxic T cells.1–3 Active specific immunization with tumor antigen has
been shown to generate immune T cells capable of recognizing antigenic peptides presented
on tumor cells.3 However, successful activation of tumor-specific T cells does not correlate
with tumor response and only a small percentage of patients demonstrate objective tumor
regression.4,5
It is already known that melanoma and other tumors develop sophisticated immune evasion
mechanisms6 that can explain the failure of current immunotherapies. One important tumor
escape mechanism is represented by the loss or downregulation of major histocompatibility
complex (MHC) Class I antigens in tumor cells that have been frequently observed in a
variety of human malignancies derived from HLA Class I positive epithelia.7,8
A small proportion of melanoma patients develop a mix response after therapy, when some
metastatic lesions regress, while other progress in the same patient.9,10 These patients are
extremely valuable since they allows us to consider solely the tumor’s determining factors in
immune responsiveness excluding variation in the genetic background of different patients
or external variables affecting the potency of identical treatments provided at different
times.11 The information obtained can help to explain the molecular basis of tumor immune
rejection and the tumor mechanism of immune escape.
Our laboratory has had the opportunity to analyze two of such mixed-response melanoma
patients after different immunotherapy treatments. In particular, we obtained five metastases
(three progressing and two regressing) from Patient 1 (M1)12 and ten metastases (two
progressing and eight regressing) from Patient 2 (M2).13 To date, no comparative analysis of
simultaneous lesions with different clinical evolution has been performed at the global
transcript level.
We present in this article the whole genome transcriptional analysis of various lesions
obtained from two melanoma patients and related it with HLA expression data. Our results
clearly indicate for the first time that the rejection pattern in melanoma lesions from both
patients is the same and include activation of genes involved in antigen presentation,
immune rejection and interferon pathways. In contrast, these particular groups of genes are
downregulated in progressing melanoma lesions. The final consequence of this activation is
a clear difference in HLA Class I cell surface expression that could explain why some
lesions are rejected and others are not.
Material and Methods
Patients, clinical protocols and tumor specimens
We studied 15 metastases from two patient treated with immunotherapy.14 Both patients
showed a mixed response to treatment: some lesions disappeared, others reduced the size,
some metastases grew bigger and some new lesions appeared. Six subcutaneous metastases
were removed from Patient 1 after 35 days with M-VAX treatment and sent to our
laboratory.12 In this study one of the regressing metastases was not analyzed analyzed due to
lack of material. Two of the remaining metastases (designated M1-VAX.R1 and M1-
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VAX.R2) were regressing at the time of excision, whereas the other three were progressing
(designated M1-VAX.P1, M1-VAX.P2, M1-VAX.P3). We obtained ten metastases from
Patient 2,13 five subcutaneous lesions were obtained after 10 months with alpha-INF-2b
treatment and five lymph node metastases were obtained 10 days after finishing a 6-week
M-VAX vaccination treatment. We obtained one progressing and four regressing lesions
after each treatment from this patient. Samples obtained after IFNα-2b treatment were
designated as M2-INF.R1, M2-INF.R2, M2-INF.R3, M2-INF.R4 and M2-INF.P1. Samples
obtained after M-VAX were named M2-VAX.R1, M2-VAX.R2, M2-VAX.R3, M2-
VAX.R4 and M2-VAX.P1. The detailed clinical history of the patients was previously
described.12,13 Samples were obtained from the Department of Dermatology, Hospital
Virgen de la Macarena, Sevilla, Spain. Informed consents and approval of the research
protocol by the institutional review board were obtained. All metastases were removed from
the patients at the same time after immunotherapy and snap-frozen in liquid nitrogen-cooled
iso-pentane. Tumor response was established according to PET and CT scans.
Tumor cells microdissection
Cryopreserved 6-μm-thick tissue sections were fixed in 70% ethanol and stained with a
0.05% wt/vol solution of toluidine blue and microdissected using a Laser micromanipulator
(PALM Microlaser Systems, ZEISS). Microdissected fragments were collected in PALM
Adhesive Caps.
Total RNA isolation and amplification
Total RNA (tRNA) from whole sections and micro-dissected frozen tumor cells were
isolated using the miRNeasy Mini kit (QIAGEN, Westburg, Leusden, The Netherlands). The
quality of tRNA was tested with Agilent Bioanalyzer 2000 (Agilent Technologies, Santa
Clara, USA). For gene expression studies, tRNA obtained from the whole frozen section
was amplified into antisense RNA (aRNA) as previously described.15 Reference for human
arrays consisted of pooled PBMCs from four normal donors. Human reference total RNA
was also amplified into antisense RNA.
Microarray performance and data processing
Array quality was documented as previously described.16 Both reference and test aRNA
were directly labeled using ULS aRNA Fluorescent Labeling kit (Kreatech) with Cy3 for
reference and Cy5 for test samples and cohybridized at 45 °C for 18 hr into 36k whole
genome human array.15 After incubation, the arrays were washed and stained in the fluidics
station using GeneChip® Hybridization, Wash, and Stain Kit (Affymetrix, Santa Clara,
USA). The data were uploaded to the mAdb databank http://nciarray.nci.nih.gov, further
analyzed using BRBArray-Tools developed by the Biometric Research Branch, National
Cancer Institute http://linus.nci.nih.gov/BRBArrayTools.html17 and clustered by TreeView
software.18,19 Unsupervised analysis was used for class discovery using the stanford cluster
program applying standard gene filtering parameters (80% gene presence across all
experiments and at least 1.5-fold ratio change) and Treeview program for visualization.
Average gene ratios were normalized and displayed according to uncentered correlation
algorithms. Class comparison was performed using parametric unpaired Student’s t test to
identify differentially expressed genes among progressing and regressing tumors. Validation
by quantitative polymerase chain reaction (q-PCR) of the gene sets were not performed due
to the fact that we have previously shown the present method for RNA amplification is
robust and yields results comparable to those obtained by qPCR.16 Moreover, salient gene
products were validated at the protein expression level by immunostaining. Gene function
interpretation was based on GeneOntology software, while pathway analysis was based on
Ingenuity Pathways Analysis (IPA) software. Primary microarray data are available in
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NCBI’s Gene Expression Omnibus public database (microarray platform, GPL7088;
microarray data, GSE26383).
Quantitative RT-PCR of isolated tumor cells
RT products from microdissected metastases were analyzed for the expression of HLA-A, B
and C loci by quantitative PCR. To control for variations in the amounts of RNA, G6PDH
and HPRT were tested as a housekeeping gene. All PCR reactions were performed in a
Light Cycler instrument using LC-FastStart DNA master probes kit and LC-FastStart DNA
SYBR Green I Kit (Roche Diagnostics, Manheim, Germany). For G6PDH and HPRT we
used commercial kits (Roche Diagnostics, Manheim, Germany). Amplification reactions of
HLA loci were described previously.13
Immunohistological analysis
Immunohistological analysis was performed using Novolink® polymer detection system kit
(Novocastra, Newcastle, United Kingdom). For HLA Class II staining we used GRB-1 mAb
(anti-HLA-DR). Infiltration pattern was studied with, OKT8 mAb (anti CD8) OKT3 mAb
(anti CD3) (hybridomes obtained from ATTC, Manassas, VA) and RPA-T4 mAb (anti
CD4), (BD Biosciences Pharmingen, Belgium).
Results
Regressing metastases display upregulation of antigen presentation and immune rejection
patterns
Unsupervised analysis clustering lesions according to its general profile expression showed
that metastases are first grouped according to the patient and second according to the
response (Supporting Information Fig. S1). To understand the different response between
progressing and regressing metastases from both patients we perform a high stringency class
comparison between the progressing and regressing metastases from both patients using a
nominal cut-off significance level of p ≤ 0.001. This analysis identified 167 genes
differentially expressed between regressing and non regressing lesions—most of which were
associated with antigen presentation function and acute immune response (Supporting
Information Table S1; Fig. 1). To gain a more comprehensive portrait of the transcriptional
signatures associated with rejection, we performed gene enrichment analysis comparing
regressing and nonregressing lesions at a nominal significance cut-off p-value ≤ 0.01. This
analysis identified 540 transcripts differentially expressed between the two phenotypes (Fig.
1). Expression pattern in regressing metastases is related to a release of interferon gamma
from infiltrating T lymphocytes. The upregulated genes (IRF-1, STAT-1 AIF-1, CCL5,
GBP1, GBP2…) are mainly involved in Type II interferon response. We observed this
pattern in metastases obtained after MVAX and even after Type I interferon alpha 2b
treatment. The enriched data set (540 transcripts) was analyzed by ingenuity pathway
analysis (IPA) software to obtain the molecular pathways differentially expressed in
regressing versus progressing melanoma lesions. The top 15 most significantly altered
pathways found among the ~400 included in IPA were upregulated in regressing metastases
and were related to mechanisms associated with immune-mediated tissue-specific
destruction (Fig. 2a). These pathways include cytotoxic T-lymphocyte apoptosis of target
cells, allograft rejection signaling and different autoimmune disorders. Figure 2b shows the
top ranking self-organizing network by IPA based on this data set. Interaction network
clearly demonstrated upregulation of IRF and antigen presentation networks in regressing
metastases. Interesting we did not find any downregulated gene in this network,
demonstrating the consistency of the results.
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We found that progressing metastases have upregulate genes involve in cellular metabolism
(Fig. 1). This pattern is due to the cellular growth of tumor cells. We did not find markers of
inhibitory immune cells, as regulatory T cells (Tregs) or myeloid derived suppressor cells
(MDSC), in progressing metastases (Supporting Information Table S1). The only escape
mechanism detected by whole transcriptional analysis is the downregulation of HLA Class I
molecules.
To determine the major role of the immune rejection against the regressing lesions in each
patient separately, we compared progressing versus regressing lesions inside each patient.
The results are showed in Supporting Information Figure S2. Both patients showed parallel
differences between the two groups of metastases. Most significantly altered IPA canonical
pathways were similar in both patients and maintain the same pathways observed when we
compared all metastases together (Supporting Information Figs. S2 a and c), including
antigen presentation, cytotoxic T-lymphocyte apoptosis of target cells, allograft rejection
signaling and different autoimmune disorders. Antigen presentation, immune infiltration and
IRF activation networks were mostly involved in discriminating responding from non
responding lesions in spite of the different patient genetic background and different
treatments (Supporting Information Figs. S2 b and d).
Chromosomal distribution of genes differentially expressed between progressing and
regressing metastases demonstrated a great enrichment for transcripts located in
Chromosome 6 (Supporting Information Fig. S3), where antigen presentation and many
inflammation genes are located.
The results clearly showed an acute immune response in regressing metastases, with most
transcripts associated with immune rejection response being upregulated. These included
activation of antigen presentation, interferon stimulated genes (ISGs), immune effector
function related genes (IEFs) and several chemokines (Fig. 2 and Supporting Information
Fig. S2, network analysis).
To investigate the differences between regressing metastases after interferon and autologous
vaccination we compared regressing metastases from Patient 2 after interferon versus those
after M-VAX. IPA canonical pathways analyses using the significant genes from the high
stringency comparison showed a borderline significant upregulation of antigen presentation
in M-VAX treated regressing lesions. We found no other significant different pathways
between regressing lesions after interferon and M-VAX (Supporting Information Table S1;
Fig. S4). Therefore, there were not major differences in the regressing pathway response
after interferon and M-VAX treatment.
Immunohistological validation of immune infiltrates shows a large T-cell population inside
regressing tumors
To confirm the enhancement of immune activity in regressing lesions in both patients, we
studied the immune infiltrate in cryopreserved tissue sections. Immunostaining with
antibodies against HLA Class II DR indicated that both progressing and regressing tumor
cells were negative for HLA Class II expression, while the immune infiltrate showed strong
positive staining (Fig. 3). There was a dramatic difference in the number of infiltrating cells
between phenotypes; progressing lesions showed low number of infiltrating cells, and vice
versa for regressing lesions. Differences in HLA Class II expression documented by
microarray transcriptional analysis of bulk mRNA were not associated with enhanced tumor
cell expression, but rather with the enrichment of the tumor environment with immune cells.
The composition of the infiltrate in regressing metastases consisted mostly in CD3+ T cells
(80% of CD4+ and 20% of CD8 + cells), (Fig. 3).
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Microdissected isolated tumor cells from progressing metastases showed a reduced
expression of HLA Class I A, B and C loci
For the analysis of tumor HLA Class I expression we isolated cancer cells from frozen
tumor samples using laser microdissection to restrict the analysis to tumor cells only and
avoid sample contamination with stroma and infiltrating cells. Quantitative RT-PCR
analysis of isolated tumor cells obtained from progressing metastases in Patient 1
demonstrated low mRNA levels for HLA-A locus transcripts with residual transcription of
HLA-B and -C loci (Fig. 4). In contrast, cancer cells from regressing lesions from the same
patient showed high transcription levels of HLA-A, HLA-B and HLA-C. Similar correlation
we have previously reported in Patient 2,13 in which high mRNA levels of all three HLA
loci were observed in regressing metastases and only residual levels in progressing lesions.
Here we present data on both Patients 1 and 2 to better illustrate the similarity of the
observed correlation between low HLA Class I transcriptional expression level and the
tendency of the lesions to progress. In Patient 2 the HLA levels were higher in post M-VAX
regressing lesions compared to the lesion after IFN therapy. These data are in agreement
with the array results. The mRNA levels were also consistent with immunohistochemical
staining of HLA Class I molecules described previously.12,13
Discussion
We have observed that the differential activation of genes involved in acute inflammatory
processes (Fig. 2) between regressing and progressing melanoma lesions obtained after
immunotherapy are dramatic. Among 30,000 studied genes in regressing metastases we
mostly detected upregulation of the genes related to the immune rejection with a great
enrichment for transcripts located in Chromosome 6, where antigen presentation and many
inflammation related genes are located. We propose that these differences are due to
efficient tumor recognition and elimination of regressing metastases by the activated
immune system “triggered” by HLA Class I upregulation. However, the systemic
immunotherapy cannot induce the regression of all lesions. Because of the major differences
in HLA expression, we propose that progressing lesions are not recognized by immune cells
due to irreversible alterations in HLA Class I.
The transcriptional pattern expressed by regressing metastases was quite similar,
independently of the type of immunotherapy used. This suggests that the mechanisms
leading to tumor rejection converge in a unique pathway (Fig. 5). In this context, the
expression pattern of regressing lesions was also similar to that observed after imiquimod or
IL-2 administration in basal cell carcinoma,20,21 allograft rejection,22 graft versus host
disease, autoimmunity or acute infection resulting in clearance of pathogen.23 This has been
postulated as the existence of an immunologic constant of rejection.24,25 The molecular
mechanisms used to eliminate all of them converge in a final pathway consisting of the
expression of antigen presentation, ISGs and IEFs. The expression pattern that we have
found is ultimately an interferon Type II signature most probably mediated by a release of
interferon-gamma by tumor infiltrating T cells, even when the melanoma patient was treated
with interferon alpha2b.
Immunohistochemistry staining of tumors showed the correlation between tumor infiltration
and the expression of genomic transcripts implicated in tumor rejection (ISGs and IEFs).
Several studies have described the presence of tumor-antigen specific cytotoxic T
lymphocytes in the tumor microenvironment.23 Nevertheless, these cells are unable to
eliminate tumor cells.23 In this study, immune cells potentially induced or activated by the
immunotherapy can recognize and eliminate lesions that previously were low immunogenic
and invisible for the immune system. However, this immunomodulation occurred only in a
subset of metastases, while another group of lesions continued to grow in spite of systemic
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activation of immune surveillance mechanisms. Therefore, intratumoral factors are most
likely to be responsible for the failure of the immune response within the progressing
metastases. Genome transcriptional analysis indicates that antigen presentation is the most
critical pathway to determine tumor regression. Previous studies12,13 and microdissected
tumor from both patients confirm that specific HLA-A, B and C high expression is
associated with immune infiltrate and tumor regression, meanwhile a low or negative HLA
Class I transcription correlate with tumor progression (Table 1). Interestingly, we did not
find differences in markers corresponding to regulatory T cells (Tregs) or myeloid derived
suppressor cells (MDSC) when both types of metastases were compared.
Our observations suggest that immunotherapy promotes a modification of tumor
microenvironment, leading to a release of immune stimulating factors by immune
infiltrating cells. This immune stimulation will lead to upregulation of HLA expression in
tumor cells with reversible alterations of HLA Class I expression (“Soft” lesions) and,
subsequently, these tumor cells will be recognized and destroyed by the antigen-specific T
cells. These T cells, as they recognize tumor cells, produce more proinflammatory factors
such as IFN-γ, IL-2, TNF-α and GM-CSF.26 This, in turn, triggers a positive and self
perpetuating feedback between tumor and immune cells until tumor rejection occurs. In
contrast, if cancer cells bear irreversible defects in HLA Class I genes (“Hard” lesions),
antigen presentation remains defective after immunotherapy impairing the amplification of
the immune response in situ and promoting their escape from immune recognition.26
Our prediction is that “soft” and “hard” HLA Class I tumor lesions will coexist during the
natural history of tumor development. However after immunotherapy tumor cells with “soft”
lesion will upregulate antigen presentation and can be rejected. In contrast, those tumor cells
bearing “hard” and irreversible genetic defects will prevail and progress to kill the host.27
This clearing would lead to the selection of a tumor variant with additional alteration of
HLA Class I expression.28,29
To the best of our knowledge, this is the first comparison of the transcriptional profile of
melanoma metastases with different responses after immunotherapy in the same patient,
showing the “molecular image” of tumor rejection. Our results strongly suggest that the
genetic makeup of individual tumor cells is a major factor determining immune
responsiveness. In particular the capacity to modulate tumor HLA Class I expression.
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expression pattern clustering of melanoma metastases obtained from comparing regressing
versus progressing metastases (p = 0.001). Genes upregulated in regressing metastases are
represented in red, genes overexpressed in progressing metastases are represented in green.
Most of the genes upregulated in regressing metastases belong to the immune response. Key
genes involved in immunological rejection (antigen presentation, immune effectors factors
and interferon stimulates genes) are included in the orange box, metabolism genes
upregulated in progressing metastases are included in the green box.
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Class comparison between progressing and regressing metastases in both patients. (a) Top
15 first canonical pathways ranking according to significance level (Fisher exact test −log p-
value) based on the 540 identified genes using gene enrichment (p = 0.01) analysis. Blue bar
represent the p-value of the comparison and yellow line represents the change ratio of the
pathway. Red bar represent the percentage of genes upregulated inside each pathway in
regressing lesions meanwhile green bars represent downregulated ones, yellow line in this
graphic represents the p-value of the comparison. All the most significant pathways belong
to the immune response and are upregulated in regressing lesions. (b) Antigen presentation
plus IRF-1 self organizing network according to IPA analysis based on the 540 identified
genes derived from the low stringency analysis. Upregulated genes in regressing metastases
are represented in red. Fold-change of the gene is represented by color intensity. The figure
shows a consistent activation of the immune genes inside regressing lesions. The analysis
did not identify any downregulated gene in the network.
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Immunoperoxidase staining of frozen sections of metastases: (a) tumor cells from both
progressing and regressing metastases do not express HLA-DR. The staining shows a high
degree of HLA-DR positive cellular infiltration in regressing metastasis; in contrast, the
progressing lesions have very little infiltration. (b) CD3 staining corresponds to T
lymphocyte infiltration (c and d). The number of CD4 positive cells in the infiltrate is higher
than the number of CD8 cells.
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Normalized mRNA levels in tumor cells isolated by laser microdissection from melanoma
patients. The progressing metastases (P) obtained from both patients showed low residual
levels of HLA-A, -B and -C loci. In contrast, the regressing tumor cells (R) displayed a high
transcription of the tree HLA loci. Regressing metastases obtained after M-VAX treatment
in patient M2 showed higher HLA loci expression than those obtained after interferon α 2b.
Carretero et al. Page 13











A common pathway of T cell mediated rejection is showed in different pathological entities.
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